A hyperimmune ovine antibody-based therapeutic candidate against Crimean–Congo haemorrhagic fever virus targeted to the Gn and Gc glycoproteins: high antibody levels with neutralization activity but lack of protective efficacy in a mouse model
Rattachement africain : gb, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Crimean-Congo haemorrhagic fever virus (CCHFV) is a tick-borne pathogen that has a wide geographical range and has the potential to cause severe disease in those infected. There are no currently approved vaccines or therapeutics, so the development and assessment of new approaches are urgently required. Methods: A polyclonal antibody-based therapeutic was developed based on immunization of sheep with the major glycoprotein antigens from CCHFV. Along with purified immunoglobulin G (IgG) from hyperimmune sera, fragmentation of the F(ab')2 region was also performed. The pharmacokinetic properties were assessed in mice, and efficacy was ascertained in a live CCHFV challenge model. Results: Candidate polyclonal antibody-based therapies were developed, demonstrating strong binding to the CCHFV envelope glycoprotein and neutralizing activity. The ovine whole IgG demonstrated stability post-delivery compared to a rapid reduction of the F(ab')2 fragment in the circulation. Efficacy testing when delivered either as a single dose before challenge or as daily dosing for 7 days starting on the day of challenge showed no demonstrable evidence of protection against infection. Conclusions: Despite protection observed from vaccine candidates using the CCHFV glycoprotein as an antigen and administration of convalescent sera, the ovine antibody-based therapeutics did not confer similar efficacious effects in the mouse preclinical model.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A hyperimmune ovine antibody-based therapeutic candidate against Crimean–Congo haemorrhagic fever virus targeted to the Gn and Gc glycoproteins: high antibody levels with neutralization activity but lack of protective efficacy in a mouse model
- Date Crossref
- 01/04/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Defence Science and Technology Laboratory pays non établi dans la noticeOrganisme public
-
Oxford Technologies (United Kingdom) pays non établi dans la noticeEntreprise
-
Therapeutic Proteins International (United States) pays non établi dans la noticeEntreprise
-
UK Health Security Agency (UKHSA) pays non établi dans la noticeOrganisme public
-
Oxford Expression Technologies pays non établi dans la noticeInstitution
-
International Therapeutic Proteins Ltd pays non établi dans la noticeEntreprise
-
SERB Pharmaceuticals pays non établi dans la noticeInstitution
Defence Science and Technology Laboratory, Oxford Technologies (United Kingdom) et Therapeutic Proteins International (United States), avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.